IP-10 Epitope Antibody Specificity for Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IP-10 related diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus are inadequate in effectively suppressing IP-10 activity, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of novel epitopes for anti-IP-10 monoclonal antibodies and their antigen-binding fragments, which specifically recognize and bind to IP-10, enabling the creation of pharmaceutical compositions for treating or preventing these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IP-10 related diseases are used, then disease management is maintained, but IP-10 activity suppression is insufficient leading to suboptimal therapeutic outcomes
Solution Approach 1:
The patent identifies and targets specific amino acid sequences (epitopes) within the IP-10 protein structure, particularly focusing on regions with high conservation and functional importance. By changing the parameter of antibody specificity to target these precise epitopic regions, the therapeutic intervention achieves superior IP-10 activity suppression compared to current treatments.
Solution Approach 2:
The IP-10 protein is segmented into distinct epitopic regions, with particular emphasis on the C-terminal region (amino acids 61-98) and specific subsequences containing critical residues. This segmentation allows for targeted antibody design that specifically binds to functional epitopes, thereby more effectively suppressing IP-10 activity while improving therapeutic reliability.
2Object-affected harmful factors
If novel epitopes and antibodies are developed, then IP-10 activity suppression is enhanced, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the critical epitopic sequences from the full IP-10 protein structure, specifically identifying key amino acid regions (such as the C-terminal region and conserved subsequences) that are essential for IP-10 function. By taking out only these critical epitopic portions as targets, the treatment achieves enhanced suppression without requiring complex multi-component interventions, thus managing complexity.
Solution Approach 2:
The identified epitopes represent universal target regions that are conserved across different IP-10 contexts and disease states. A single antibody targeting these universal epitopes can suppress IP-10 activity across multiple disease conditions (multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus), providing multi-functionality that reduces overall treatment complexity despite the enhanced suppression capability.
Data Source
AI summary
The present invention relates to a novel epitope of IP-10 (IFN-γ-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.